Keystone Financial Group (Kentucky)’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$207K Buy
+4,320
New +$186K 0.01% 520
2025
Q3
Sell
-2,976
Closed -$205K 465
2025
Q2
$205K Buy
+2,976
New +$202K 0.02% 395
2025
Q1
Sell
-2,451
Closed -$211K 405
2024
Q4
$211K Sell
2,451
-481
-16% -$52K 0.02% 359
2024
Q3
$349K Buy
2,932
+86
+3% +$11.5K 0.04% 255
2024
Q2
$406K Buy
2,846
+453
+19% +$60K 0.15% 100
2024
Q1
$307K Buy
+2,393
New +$285K 0.04% 254

Other funds holding NVO

Keystone Financial Group (Kentucky)'s NVO Position: Q2 2026 in Review

Keystone Financial Group (Kentucky) opened a new position in Novo Nordisk (NVO) in Q2 2026: 4,320 shares worth $207K. The stake represents 0.01% of the portfolio and ranks #520 among its holdings. This is a return to the name: Keystone Financial Group (Kentucky) previously reported a position in NVO as recently as Q2 2025.

Keystone Financial Group (Kentucky) first reported a position in NVO in Q1 2024 and has held it in 6 quarters since. The position peaked at $406K in Q2 2024. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Keystone Financial Group (Kentucky) held 4,320 shares of Novo Nordisk worth $207K as of Q2 2026.
  • Novo Nordisk was a new Keystone Financial Group (Kentucky) position in Q2 2026.
  • Novo Nordisk made up 0.01% of Keystone Financial Group (Kentucky)'s portfolio in Q2 2026, its #520 holding.
  • Keystone Financial Group (Kentucky) first reported a position in Novo Nordisk in Q1 2024 and has held it in 6 quarters since.
  • Keystone Financial Group (Kentucky)'s Novo Nordisk position peaked at $406K in Q2 2024.
  • 1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Keystone Financial Group (Kentucky)'s 13F filing for Q2 2026, filed 29 Jul 2026.